Labcorp Expands Sexually Transmitted Infection (STI) Test Offerings with Rapid Syphilis Test Read more about Labcorp Expands Sexually Transmitted Infection (STI) Test Offerings with Rapid Syphilis Test
Labcorp to Announce Third Quarter Financial Results on October 24, 2024 Read more about Labcorp to Announce Third Quarter Financial Results on October 24, 2024
Cinven to sell minority stake in SYNLAB to strategic investor Labcorp Read more about Cinven to sell minority stake in SYNLAB to strategic investor Labcorp
Labcorp Prices $650,000,000 in 4.350% Senior Notes Due 2030, $500,000,000 in 4.550% Senior Notes Due 2032 and $850,000,000 in 4.800% Senior Notes Due 2034 Read more about Labcorp Prices $650,000,000 in 4.350% Senior Notes Due 2030, $500,000,000 in 4.550% Senior Notes Due 2032 and $850,000,000 in 4.800% Senior Notes Due 2034
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health Read more about Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Labcorp to Acquire Select Outreach Services from Ballad Health Read more about Labcorp to Acquire Select Outreach Services from Ballad Health
Labcorp to Speak at the Baird 2024 Global Healthcare Conference Read more about Labcorp to Speak at the Baird 2024 Global Healthcare Conference
Labcorp Finalizes Acquisition of Select Assets of Invitae Read more about Labcorp Finalizes Acquisition of Select Assets of Invitae
Labcorp Receives FDA De Novo Marketing Authorization for PGDx elio™ plasma focus Dx Read more about Labcorp Receives FDA De Novo Marketing Authorization for PGDx elio™ plasma focus Dx
